Objectives: The purpose of the present investigation was to evaluate the influence of solid dispersion of pH dependent and pH independent Eudragit polymers on the sustained release metformin hydrochloride matrix tablets. Materials and methods: Matrix formulations were prepared by direct compression techniques. The excipients used in this study did not alter physicochemical properties of the drug, as tested by FTIR and DSC. All the batches were evaluated various physical parameters. The in vitro drug dissolution and SEM studies were also carried out. Mean dissolution time is used to characterize drug release rate from a dosage form. Results and discussion: Among the different examined polymer blends, Eudragit RLPO with S100 and Ll00 matrix...
The aim of the present study was to design an oral sustained release matrix tablet of highly water s...
Purpose: To develop and characterize an oral extended-release matrix tablet of metformin hydrochlori...
Aim: The present investigation concerns the development of controlled release matrix tablet of Dilti...
Objectives: The purpose of the present investigation was to evaluate the influence of solid dispersi...
Objectives: The purpose of the present investigation was to evaluate the influence of solid dispersi...
Metformin hydrochloride is recommended globally as first line therapy due to its favorable profile o...
Aims: The present investigation studied effect of polymethacrylates Eudragit RSPO, Eudragit RLPO and...
Metformin hydrochloride is an antidiabetic agent which improves glucose tolerance in patients with t...
The effect of the polymer system modified Clorhidrato Eudragit E-100, as modified release excipien...
Aims: The present investigation studied effect of polymethacrylates Eudragit RSPO, Eudragit RLPO and...
Tablets exhibiting extended drug release have in many therapeutical applications shown both complian...
Tablets exhibiting extended drug release have in many therapeutical applications shown both complian...
The objective of the present study was to develop diclofenac sodium tablets from polymeric matrices ...
Copyright © 2012 Amitava Roy et al. This is an open access article distributed under the Creative Co...
Purpose: To develop and characterize an oral extended-release matrix tablet of metformin hydrochlori...
The aim of the present study was to design an oral sustained release matrix tablet of highly water s...
Purpose: To develop and characterize an oral extended-release matrix tablet of metformin hydrochlori...
Aim: The present investigation concerns the development of controlled release matrix tablet of Dilti...
Objectives: The purpose of the present investigation was to evaluate the influence of solid dispersi...
Objectives: The purpose of the present investigation was to evaluate the influence of solid dispersi...
Metformin hydrochloride is recommended globally as first line therapy due to its favorable profile o...
Aims: The present investigation studied effect of polymethacrylates Eudragit RSPO, Eudragit RLPO and...
Metformin hydrochloride is an antidiabetic agent which improves glucose tolerance in patients with t...
The effect of the polymer system modified Clorhidrato Eudragit E-100, as modified release excipien...
Aims: The present investigation studied effect of polymethacrylates Eudragit RSPO, Eudragit RLPO and...
Tablets exhibiting extended drug release have in many therapeutical applications shown both complian...
Tablets exhibiting extended drug release have in many therapeutical applications shown both complian...
The objective of the present study was to develop diclofenac sodium tablets from polymeric matrices ...
Copyright © 2012 Amitava Roy et al. This is an open access article distributed under the Creative Co...
Purpose: To develop and characterize an oral extended-release matrix tablet of metformin hydrochlori...
The aim of the present study was to design an oral sustained release matrix tablet of highly water s...
Purpose: To develop and characterize an oral extended-release matrix tablet of metformin hydrochlori...
Aim: The present investigation concerns the development of controlled release matrix tablet of Dilti...